Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation

An Exploratory Clinical Trial to Evaluate the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation

An exploratory clinical trial to evaluate the pharmacokinetic characteristics of I.V. Hepabig injection used for prevention of hepatitis B relapse after liver transplantation.

Inclusion Criteria:

• Male or female ≤18 years old
• Patients who understand the informed consent form and signed the form voluntarily
• Patients who underwent liver transplantation due to HBV related disease and will be treated for prevention of hepatitis B relapse after liver transplantation

Exclusion Criteria:

• Multi-organ recipient or reimplantation
• IgA Deficiency
• Serious nephropathy
• Serious cardiovascular system failure within 6 months
• Ischemic or hemolytic anemia
• Condition of immunosuppression and immunodeficiency
• Hypersensitivity or allergic to blood products
• HIV or HCV positive
• Participation to other clinical trial within 3 months
• Pregnancy or breast feeding
• Those who the investigator determines inappropriate to participate